Insmed Inc (INSM)vsMapLight Therapeutics, Inc. Common Stock (MPLT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MPLT
MapLight Therapeutics, Inc. Common Stock
$18.14
+6.83%
HEALTHCARE · Cap: $774.97M
Smart Verdict
WallStSmart Research — data-driven comparison
MPLT leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MPLT
Avoid21
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MPLT
MPLT has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MPLT
The primary concerns for MPLT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while MPLT is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
MPLT generates stronger free cash flow (-32M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
MapLight Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
MapLight Therapeutics, Inc. is a pioneering biotechnology firm focused on advancing novel therapies for serious neurological and psychiatric disorders. Leveraging its proprietary platform, the company targets complex biological pathways to develop transformative treatment solutions that aim to significantly improve patient outcomes. With a strong dedication to scientific excellence and a robust clinical development pipeline, MapLight is strategically positioned to tackle critical unmet medical needs, establishing itself as a prominent entity in the rapidly evolving neurotherapeutics landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?